Pharmaceuticals

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

A landmark survey reveals a stunning bipartisan mandate on reproductive health, showing a vast majority of Republican voters support protecting access to EC.

Tiziana Life Sciences has dosed the final patient in a key trial for its nasal MS drug, foralumab. With data imminent, this could be a breakthrough for an untreatable form of the disease.

A landmark FDA approval for Merck's KEYTRUDA and Gilead's Trodelvy creates a powerful new first-line treatment for advanced triple-negative breast cancer.

Oblenio Bio's oversubscribed Series B will advance a novel tri-specific T-cell engager, aiming to reset the immune system without harsh side effects.

ProQR Therapeutics secures a crucial $59.2M, extending its runway and gaining a powerful endorsement from partner Eli Lilly for its Axiomer RNA editing platform.

A new CMS program offers seniors blockbuster obesity drugs for $50. But this temporary fix raises profound questions about cost, access, and our healthcare future.

Insmed and EMBARC's 3,000-patient study of brensocatib aims to do more than treat a chronic lung disease—it aims to fundamentally alter its course.

Transgene unveils a scalable mpox vaccine using its cancer immunotherapy tech. Can this strategic pivot disrupt the market and fix global supply gaps?

A new license for C-Ray Therapeutics is more than a permit; it's a key move in Beijing's strategy to dominate the high-stakes radiopharmaceutical market.

ARS Pharmaceuticals' needle-free allergy spray, neffy, faces a major setback with commercial insurers, forcing a strategic pivot toward fiscal discipline.

Passage Bio finds a lifeline in a reverse merger with Remix Therapeutics, a rising RNA star. But what does this deal truly mean for shareholders and the future of cancer treatment?

The FDA has approved TRYNGOLZA, the first drug to reduce triglycerides and acute pancreatitis risk, marking a new era for millions and a pivotal moment for Ionis.

A small biotech reports its novel curcumin gel eases sickle cell pain. But its strategy of pre-approval access via pharmacies is a high-stakes economic gamble.

Kadima Neuropsychiatry sues NRx Pharma, alleging deceit in a failed acquisition. The case reveals the high stakes of corporate integrity and financial truth.

The $2B market for chronic hives is exploding, with new drugs from Sanofi, Celldex, and Novartis creating a seismic shift for patients and investors.

A new partnership aims to leverage corporate science and community trust to reverse declining cancer screenings. But can this model truly bridge the gap?

A new RNA therapy for obesity is advancing in trials. It promises to reduce harmful visceral fat, preserve muscle, and may only require a twice-yearly dose.

A landmark deal brings VIZZ, a once-daily presbyopia treatment, to Australia and New Zealand, promising millions a life with less reliance on reading glasses.

As McKesson prepares its August 5th earnings, all eyes are on its strategic overhaul. Will bold moves in oncology and tech deliver on profit promises?